ANIMATRIX CAPITAL LLP UNAUDITED ABBREVIATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2015



CONTENTS

,		Page
	Abbreviated balance sheet	1 - 2
,	Notes to the abbreviated accounts	3 - 7

ABBREVIATED BALANCE SHEET AS AT 31 MARCH 2015

		2015		2014	
	Notes	£	£	. £	£
Fixed assets					
Tangible assets	2		16,452		15,403
Investments	2		18,836,327		10,785,976
			18,852,779		10,801,379
Current assets					
Debtors	3	3,049,445		3,169,938	
Cash at bank and in hand		124,912		398,869	
		3,174,357		3,568,807	
Creditors: amounts falling due within one year		(122,663)		(60,053)	
			0.054.004		
Net current assets			3,051,694		3,508,754
Total assets less current liabilities			21,904,473		14,310,133
Creditors: amounts falling due after more than one year			(36,536,751)		(35,031,871)
•					
NET ASSETS ATTRIBUTABLE TO MEMBERS			(14,632,278)		(20,721,738)
REPRESENTED BY:					
Loans and other debts due to members within one year					
Other amounts			89,472		-
			89,472		-
Members' other interests:					
Other reserves classified as equity			(21,276,838)		(21,276,838)
Revaluation reserve			5,998,988		-
Members capital	•		556,100		555,100
			(14,632,278)		(20,721,738)
TOTAL MEMBERS' INTERESTS					
Loans and other debts due to members			89,472		_
Members' other interests			(14,721,750)		(20,721,738)
			(14,632,278)		(20,721,738)

ABBREVIATED BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2015

For the financial year ended 31 March 2015 the limited liability partnership was entitled to exemption from audit under section 477 of the Companies Act 2006 (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008) relating to small limited liability partnerships.

The members acknowledge their responsibility for complying with the requirements of the Companies Act 2006 (as applied to limited liability partnerships) with respect to accounting records and the preparation of financial statements.

These abbreviated accounts have been prepared in accordance with the provisions applicable to limited liability partnerships subject to the small limited liability partnerships' regime within Part 15 of the Companies Act 2006.

Approved by the Members for issue on ... 22" DECSMOSA 2315

R C G Lywood

Designated Member

Limited Liability Partnership Registration No. OC347020

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 31 MARCH 2015

1 Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention modified to include the revaluation of freehold land and buildings and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The financial statements have been prepared in accordance with the Statement of Recommended Practice (SORP); "Accounting by Limited Liability Partnerships", revised in 2010 and the Companies Act 2006.

1.2 Going concern

R C G Lywood, a designated member, has provided assurances of his ongoing support to the limited liability partnership. At the balance sheet date the Limited Liability Partnership owed R C G Lywood £36,536,751 and has received assurance that it is not currently the intention of R C G Lywood to call upon the loan balance until such time as the limited liability partnership has sufficient resources to settle the liability. On the basis of these assurances, the members consider it appropriate to prepare the financial statements on the going concern basis.

1.3 Compliance with accounting standards

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and the Limited Liability Partnership Statement of Recommended Practice, which have been applied consistently.

1.4 Turnover

Revenue is recognised when the service is performed or when loan interest is earned to the extent that it is probable that economic benefits will flow into the LLP and excludes value added tax.

1.5 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on a straight line basis at the following annual rates in order to write off the cost of each asset over its expected useful life, as follows:

Plant and machinery

25%

1.6 Investments

Listed investments are stated at market value. All other fixed asset investments are stated at cost less provision for diminution in value.

1.7 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.

1.8 Group accounts

The financial statements present information about the limited liability partnership as an individual undertaking and not about its group. The limited liability partnership and its subsidiary undertaking comprise a small-sized group. The limited liability partnership has therefore taken advantage of the exemptions provided by section 399 of the Companies Act 2006 (as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008) not to prepare group accounts.

2

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2015

Fixed assets	Tanaihla	Invactments	Total
	Tangible assets	Investments	iotai
	£	£	£
Cost or valuation	,	~	~
At 1 April 2014	22,594	15,944,191	15,966,785
Additions	7,465	2,398,229	2,405,694
Revaluation	-	5,998,988	5,998,988
At 31 March 2015	30,059	24,341,408	24,371,467
Depreciation			
At 1 April 2014	7,191	5,158,215	5,165,406
Charge for the year	6,416	346,866	353,282
At 31 March 2015	13,607	5,505,081	5,518,688
Net book value			
At 31 March 2015	16,452	18,836,327	18,852,779
At 31 March 2014	15,403	10,785,976	10,801,379
			

Holdings of more than 20%

The limited liability partnership holds more than 20% of the share capital of the following companies:

Company	Country of registration or	Shares held	
	incorporation	Class	%
Subsidiary undertakings			
Zoragen Biotechnologies LLP	England & Wales	LLP Member	90.00
RVI LLP	England & Wales	LLP Member	78.00
Animatrix Capital Altermune	England & Wales	Ordinary	
Limited			100.00
Origin Sciences Limited	England & Wales	Ordinary	53.00
The Jolly Frog Limited	England & Wales	Ordinary	100.00
L&L Research LLP	England & Wales	LLP Member	100.00
Nanoclave Technologies LLP	England & Wales	LLP Member	60.00
Loxbridge Research LLP	England & Wales	LLP Member	51.00
Loxbridge Altermune Limited	England & Wales	Ordinary	78.00
Agalimmune Ltd.	England & Wales	Ordinary	76.00
Altermune Limited	England & Wales	Ordinary	100.00
WZVI Limited	England & Wales	LLP Member	100.00
Frameshift Limited *	England & Wales	Ordinary	51.00
Agalimmune Inc. *	USA	Ordinary	58.00
Colonix Limited *	England & Wales	Ordinary	53.00
Freenome LLC *	USA	LLC Member	51.00

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2015

2	Fixed assets			(Continued)
	Participating interests	,	•	
	Mutiny Kites LLP	England & Wales	LLP Member	50.00
•	Second Legs LLP	England & Wales	LLP Member	33.00
	P3P Partners LLP	England & Wales	LLP Member	25.00
	P3P Project Development	England & Wales	Ordinary	
	Limited	•	·	25.00
	Finsen Technologies Limited *	England & Wales	Ordinary	27.00
	Premaitha Health PLC	England & Wales	Ordinary	29.00
	Altermune Technologies LLC *	USA	Ordinary	48.00

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2015

2 Fixed assets (Continued)

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows:

		Capital and reserves	Profit/(loss) for the year
		2015	2015
	Principal activity	£	£
Zoragen Biotechnologies LLP	Nucleic acid detection		
	research	333,141	353,402
RVI LLP	Dormant	1,000	-
Animatrix Capital Altermune	Group financing company		
Limited		(22,495)	(475,900)
Origin Sciences Limited	Diagnostic & medical services	(3,337,800)	(1,080,612)
The Jolly Frog Limited	Public house	(495,832)	(94,634)
L&L Research LLP	Dormant	(366,422)	-
Nanoclave Technologies LLP	Decontamination devices	375,577	(63,351)
Loxbridge Research LLP	Medical research consultancy	4,051,385	(255,192)
Loxbridge Altermune Limited	Medical research	(4,576,840)	(476,821)
Agalimmune Ltd.	Development of applications in the field of cancer		
	immunotherapy	(2,450,562)	(1,402,668)
Altermune Limited	Medical research	(156,503)	(156,603)
WZVI Limited	Research and development	(3,281,352)	(100,434)
Frameshift Limited *	Design and development of mobile centric web app		-
Agalimmune Inc. *	Research and development	55,185	51,356
Colonix Limited *	Dormant	1	-
Freenome LLC *	Medical research	13,406	13,406
Mutiny Kites LLP	Design and development of		
•	kites	212,996	(49,496)
Second Legs LLP	Medical crutches design & development	(2,076)	(24,837)
P3P Partners LLP	Origination and structure of	(, -,	(, , , , , , , , , , , , , , , , , , ,
	energy based products	1,394,406	(121,189)
P3P Project Development	Development of energy		, ,
Limited	generating assets	1,388,707	885,343
Finsen Technologies Limited *	Development of		•
-	decontamination devices	99,907	(66,123)
Premaitha Health PLC	Molecular diagnostics		
	business	3,896,197	(6,777,639)
Altermune Technologies LLC *	Medical research	(8,894,431)	(1,612,201)
		====	===

No accounts have been prepared for Frameshift Limited since its incorporation.

^{*} Shares held by subsidiary undertaking or participating interest.

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2015

Debtors include an amount of £2,735,645 (2014 - £2,700,064) which is due after more than one year.